Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

Tartour, Éric; Blay, Jean Yves; Dorval, Thierry; Escudier, Bernard; Mosseri, Véronique; Douillard, Jean Yves; Deneux, Laurent; Gorin, Isabelle; Négrier, Sylvie; Mathiot, Claire; Pouillart, P; Fridman, Wolf‐Herman

doi:10.1200/jco.1996.14.5.1697

Cited by 92 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C-reactive protein was introduced in this study as elevated levels in serum have been associated with shortened survival in metastatic melanoma patients and resistance to interleukin-2 therapy (Tartour et al, 1994;Mouawad et al, 1996;Tartour et al, 1996). In line with this report, we previously observed high CRP levels to indicate progression of distant metastases during therapy (Deichmann et al, 2000).…”

Section: Discussionsupporting

confidence: 59%

“…Further major sources of Il-6 may be surrounding fibroblasts or endothelial cells (Kishimoto, 1989). In vivo, CRP reflects Il-6 secretion (Klein et al, 1991) supported by high correlation between serum CRP and Il-6 concentrations in melanoma patients (Moshage et al, 1988;Castell et al, 1989;Kishimoto, 1989;Klein et al, 1991;Hirano, 1992;Tartour et al, 1996;Deichmann et al, 2000).…”

Section: Discussionmentioning

confidence: 98%

“…Besides melanoma (Tartour et al, 1994;Tartour et al, 1996), high CRP serum levels are known to indicate shorter median survival in patients suffering from other tumours such as renal cell carcinoma (Blay et al, 1992) or colorectal carcinoma (Gough et al, 1996;Nozoe et al, 1998;Mahmoud and Rivera, 2002). Thus, CRP is not exclusively increased in melanoma.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

et al. 2004

View full text Add to dashboard Cite

Lactate dehydrogenase (LDH) in serum has recently been introduced into the American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma because of its prognostic value. We hypothesised LDH to be of value in discriminating melanoma patients entering AJCC stage IV from patients staying in AJCC stages I, II or III. Lactate dehydrogenase was compared to the acute phase protein C-reactive protein (CRP), which we observed to reflect the course of melanoma metastasis in a previous report. In this prospective study, we measured LDH and CRP in the serum of 91 consecutive melanoma patients progressing into AJCC stage IV in comparison to 125 patients staying in AJCC stages I, II or III. Comparing distributions of the parameters by median values and quartiles by Mann -Whitney test, LDH was not significantly elevated in patients entering AJCC stage IV melanoma (P ¼ 0.785), whereas CRP was (Po0.001). Analysing the sensitivity and the specificity jointly by the areas under the receiver operating characteristics curves (ROC-AUC), LDH did not discriminate between the defined groups of patients (AUC ¼ 0.491; 95% confidence interval, 0.410, 0.581), whereas CRP did (AUC ¼ 0.933; 95% confidence interval, 0.900, 0.966; Po0.001). Upon logistic regression analysis to calculate the ROC-AUC values upon the predictive probabilities, LDH provided no additional information to CRP. Choosing a cutoff point of 3.0 mg l À1 , CRP yielded a sensitivity of 0.769 together with a specificity of 0.904 in diagnosing AJCC stage IV entry. Altogether, for first diagnosing AJCC stage IV melanoma, CRP is the superior serum marker when compared to the conventional LDH.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Accordingly, we characterise a responder by low nuclear grade, low CRP, metastasectomy and low LDH. Particularly, CRP (and IL-6) levels have often been found to impair IL-2 efficacy (Blay et al, 1992;Simpson et al, 1995;Tartour et al, 1996;Thiounn et al, 1997). The mechanism by which these acute phase reactants interfere with IL-2-induced tumour regression is not defined.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

et al. 2006

View full text Add to dashboard Cite

Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomyeven incomplete -C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.

show abstract

“…Biomarqueurs de l'inflammation Des dosages sériques de différents biomarqueurs liés à l'inflammation ont permis de prédire une réponse à l'immunothérapie. Ainsi, les patients qui présentent un syndrome inflammatoire reflété par des concentrations élevées d'IL-6 ou de CRP (C reactive protein, synthé-tisée par le foie et régulée par l'IL-6) et ceux chez qui on détecte un nombre élevé de lymphocytes TH17 circulants 4 sont le plus souvent résistants à des traitements par cytokines recombinantes ou par vaccination antitumorale [15,16]. Des résultats récents montrent que ce rôle prédictif de la CRP sur la réponse à l'immunothérapie l'est aussi pour la réponse à certains immunomodulateurs comme l'anticorps anti-CTLA-4 [17].…”

Section: Présence De Métastases Viscéralesunclassified

Immunothérapie des cancers

Quintin-Colonna¹,

Montier²,

Péré³

et al. 2009

bavf

View full text Add to dashboard Cite

Des cellules tumorales peuvent être reconnues par le système immunitaire qui contrôle le développement de certaines tumeurs. L’immunothérapie anti-tumorale consiste à stimuler cette immunité naturelle contre les cancers. L’emploi de cytokines recombinantes (IL-2, IFNα …) et surtout d’anticorps a permis de démontrer l’efficacité clinique de cette approche. De nouvelles stratégies d’immunothérapie reposant sur l’induction de lymphocytes T anti-tumoraux par des vaccins sont en cours de développement. L’optimisation de ces vaccins repose sur leur validation dans des modèles cliniques pertinents (tumeurs spontanées des rongeurs et des carnivores), sur leur association à des molécules permettant de lever des mécanismes de résistance de la tumeur à l’immunothérapie et sur des indications cliniques mieux définies de ces vaccins.

show abstract

Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

Cited by 92 publications

References 28 publications

Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

Immunothérapie des cancers

Contact Info

Product

Resources

About